Cartesian Therapeutics, Inc. (RNAC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 17 | 85 | 111 | 26 | 39 | 3 | 1 | - |
| Operating profit | $m | -87 | -99 | ||||||
| Net profit | $m | -69 | -26 | 35 | -220 | -77 | -130 | -154 | -77 |
| EPS reported | $ | -5.02 | -5.84 | ||||||
| Operating cashflow per share | $ | -2.85 | -2.58 | ||||||
| Capex per share | $ | 0.21 | 0.07 | ||||||
| FCF per share | $ | -3.06 | -2.65 | ||||||
| Free cash flow | $m | -79 | -78 | ||||||
| Net debt | $m | -121 | -95 | ||||||
| Book value equity | $m | -126 | -125 | ||||||
| Book value per share | $ | -4.86 | -4.19 | ||||||
| Number of shares | m | 25.97 | 29.86 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.48 | -1.50 | ||||||
| P/S LTM | x | 66.95 | 126.79 | ||||||
| P/FCF LTM | x | -2.36 | -2.40 | ||||||
| EV/EBITDA LTM | x | -0.55 | -0.47 | ||||||
| EV/Sales LTM | x | 26.74 | 119.15 | ||||||
| Earnings Yield LTM | % | -69.58% | -59.10% | ||||||
| FCF Yield | % | -42.40% | -41.73% | ||||||
| Quality | |||||||||
| ROE | % | +103.22% | +141.41% | ||||||
| ROIC | % | -28.36% | -30.78% | ||||||
| Operating margin | % | -31.00% | -66.80% | ||||||
| Gross margin | % | +100.00% | -7.66% | ||||||
| FCF/Sales | % | -2838.6% | -5291.5% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -92.81% | -96.20% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -6.26 | -1.22 | ||||||
| Net Debt/EBITDA | x | 0.82 | 0.53 | ||||||
| EBIT/Net interest | x | 0.00 | -115.80 | ||||||
| Net debt/market cap | % | +2.22% | +20.35% | ||||||
| Net debt/Equity | x | 0.96 | 0.76 | ||||||
| Gross debt/equity | x | -0.10 | -0.51 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cartesian Therapeutics, Inc. (RNAC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free